Skip to main content
. 2017 Feb 1;8(14):23008–23019. doi: 10.18632/oncotarget.14968

Figure 1. ERBB2 as target of miR-3622-5p.

Figure 1

A. Western blot analysis showing suppressed ERBB2 protein levels in SK-BR-3 breast cancer cells and SNU-216 gastric cancer cells after miR-3622-5p over-expression. The over-expression of miR-3622-5p does not alter the expression level of ERBB3. GAPDH as the internal control. Graphical presentation in the right panel. B. The seed sequence of miR-3622b-5p is complementary to the 3′-UTR of ERBB2. C. Luciferase assay showing reduction in reporter activity (relative luciferase units) after co-transfection of wild type ERBB2 3′-UTR (ERBB2-3′UTR-WT) or the fragment of ERBB2 3′-UTR lacking the candidate miR-3622b-5p binding sequence (ERBB2-3′-UTR-del) with miR-3622-5p into HEK-293T cells. ns, no significance. D. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3′UTR-WT or ERBB2-3′-UTR-del in MCF-10A cells. E. Luciferase assay showing reduction in reporter activity after transfection of ERBB2-3′UTR-WT or ERBB2-3′-UTR-del in SK-BR-3 cells.

HHS Vulnerability Disclosure